Fair value · Biodexa Pharmaceuticals Plc (BDRX) · updated 2026-10-05 · from 20-F FY2025
Biodexa Pharmaceuticals trades at $0.62. We are not reading assumptions out of that price: financials are filed in GBP; our prices are in USD, so these methods need a conversion we do not yet publish.
Everything below is unaffected: the filed statements, the filing they came from, and BDRX’s growth history are all as reported.
The filing behind these numbers
Biodexa Pharmaceuticals Plc- Revenue
- GBP 0
- Diluted EPS
- GBP 0.00
- Free cash flow
- GBP -5.6M
- operating cash flow − capital expenditure
- Diluted shares
- 54.86B
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-27 · accession 0001214659-26-003921
Open this filing on sec.govNeed BDRX data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.